Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Nov;70(2):188-94.
doi: 10.1016/j.lungcan.2010.02.006. Epub 2010 Mar 12.

Phase I Study of Autologous Dendritic Cell Tumor Vaccine in Patients With Non-Small Cell Lung Cancer

Affiliations
Clinical Trial

Phase I Study of Autologous Dendritic Cell Tumor Vaccine in Patients With Non-Small Cell Lung Cancer

Soo-Jung Um et al. Lung Cancer. .

Abstract

Background: A dendritic cell vaccine has been developed as a novel strategy for generating antitumor immunity in the treatment of cancer. The purpose of this study was to assess the maximal tolerated dose, safety, and immunologic response of a new dendritic cell vaccine (DC-Vac) into which tumor lysate was loaded by electroporation and pulse in patients with advanced non-small cell lung cancer (NSCLC).

Patients and methods: Fifteen patients with inoperable stage III or IV NSCLC were assigned to cohorts that received 3, 6, or 12 × 10(6) DC-Vac intradermally 3 times at 2 week intervals. We also evaluated immunologic and tumor responses.

Results: The maximum dose of DC-Vac (12 × 10(6)) was shown to be safe. In 5 of 9 patients, the vaccine resulted in increased interferon (IFN)-γ production by CD8+ cells after exposure to tumor lysate. Additionally, there were mixed responses which do fulfill progressive disease definition but demonstrate some clinical benefit in two patients.

Conclusion: The administration of tumor lysate-loaded autologous dendritic cells by electroporation and pulse was non-toxic and induced immunologic responses to tumor antigens. The two mixed tumor responses which were achieved may represent a potential benefit of this new DC-Vac.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback